Sudoxicam is a reversible, orally active COX inhibitor belonging to the enolic carboxamide class of nonsteroidal anti-inflammatory drugs (NSAIDs); it exhibits potent anti-inflammatory, anti-edematous, and antipyretic activities. It effectively reduces plasma inflammation markers, alleviates swelling in inflamed hind paws, and restores normal body weight gain in rats. Sudoxicam significantly inhibits edema formation in intact rats at doses as low as 0.1 mg/kg (p.o.) and suppresses ultraviolet-induced erythema in guinea pigs. It also counteracts vaccine-induced pyrexia in rats, maintaining body temperature comparable to that of uninjected controls.